Merck pays $250M to license Moderna cancer vaccine
Bio Pharma Dive
OCTOBER 12, 2022
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.
Vaccination 
245
245 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. A herpesvirus family member, CMV is spread through body fluids.
Vaccination 130
130 
Swiss startup LimmaTech licenses GSK vaccine, hires ex-CureVac chief as CEO
Bio Pharma Dive
JULY 20, 2023
The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015.
Vaccination 130
130 
Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa
Pharmaceutical Technology
APRIL 13, 2023
The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world. Julian Naidoo, CEO of Rubic One Health.
Production 279
279 
Ginkgo Bioworks to discover and develop novel vaccine adjuvantsÂ
Drug Discovery World
FEBRUARY 20, 2024
A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. Licensing for human use Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
Vaccination 52
52 
India’s CDSCO approves Bharat Biotech’s intra-nasal vaccine for Covid-19
Pharmaceutical Technology
DECEMBER 2, 2022
India’s Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine for treating Covid-19. BBV154 is claimed to be the first intra-nasal vaccine for Covid-19 in the world.
Vaccination 217
217 
Meningitis vaccine comes to the forefront with impressive study results
Pharmaceutical Technology
MAY 25, 2023
A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5
Vaccination 195
195 
Blue Water Vaccines to develop oral chlamydia vaccine
BioPharma Reporter
NOVEMBER 22, 2022
Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.
Vaccination 52
52 
Bavarian Nordic completes travel vaccine deal with Emergent
Pharmaceutical Technology
MAY 16, 2023
Bavarian Nordic has completed the acquisition of Emergent BioSolutions ’ travel vaccine portfolio for an upfront payment of $274m, with the potential for the total value to rise to $384m. Following the completion of the deal, Bavarian Nordic now boasts the only oral vaccine licensed by the U.S.
Vaccination 130
130 
BioNTech Partners with Matinas BioPharma to Develop New Delivery Technology for mRNA Vaccines
XTalks
APRIL 18, 2022
Top COVID-19 mRNA vaccine maker BioNTech is setting out to explore new and improved delivery technologies for mRNA vaccines, recently announcing a collaboration with New Jersey-based lipid nanocrystal developer Matinas BioPharma. The Pfizer-BioNTech COVID-19 vaccine Comirnaty must be stored at -90°C to -60°C.
Vaccination 105
105 
Successful clinical trial for re-engineered Covid vaccineÂ
Drug Discovery World
NOVEMBER 24, 2023
The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. million to continue development for use in the global response to future disease outbreaks. The Clamp2 trial group showed a 2.5-fold
Clinical Trials 110
110 
STAT+: Merck pays $250 million to license a Moderna skin-cancer vaccine candidate
STAT News
OCTOBER 12, 2022
Merck on Wednesday agreed to extend an ongoing collaboration with Moderna to develop a personalized vaccine for the treatment of patients with skin cancer. Moderna is getting $250 million from Merck to secure opt-in rights to the cancer vaccine candidate, called mRNA-4157.
Vaccination 98
98 
CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase III
XTalks
FEBRUARY 19, 2024
Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.
Vaccination 59
59 
Noxopharm in-licenses novel RNA tech for drug discovery and vaccines
BioPharma Reporter
DECEMBER 6, 2021
Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.
RNA 52
52 
Experimental NIH Sudan virus vaccine protects macaques
Medical Xpress
FEBRUARY 3, 2023
A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease.
Vaccination 95
95 
Moderna, Pfizer Hit with New COVID Vaccine Patent Lawsuits
BioSpace
JUNE 7, 2023
Promosome filed lawsuits Tuesday against Moderna and Pfizer/BioNTech, alleging that the vaccine developers used patent-protected mRNA technology without a license.
Vaccination 79
79 
Chinese tech giant Baidu licenses mRNA algorithm to Sanofi
pharmaphorum
NOVEMBER 23, 2021
Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs.
Licensing 101
101 
Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
BioTech 365
NOVEMBER 22, 2021
Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against … (..)
Licensing 52
52 
New malaria vaccine licensed for use in Ghana
BioPharma Reporter
APRIL 13, 2023
The R21/Matrix-M malaria vaccine, developed by the University of Oxford, has received its first regulatory clearance.
Vaccination 52
52 
Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.
Vaccination 162
162 
World Tuberculosis Day 2024: New vaccines offer hope
Drug Discovery World
MARCH 27, 2024
The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. According to GlobalData, there are 11 vaccines in late-stage development for TB globally.
Vaccination 52
52 
Partnership to fast-track MERS vaccine
Drug Discovery World
JANUARY 8, 2024
UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS).
Vaccination 59
59 
COVID-19 News: Vaxart Posts Phase I Data on Oral Vaccine, BMS Licenses mAb
BioSpace
FEBRUARY 2, 2021
The vast majority of COVID-19 vaccines on the market or in development are administered through an injection, but Vaxart is attempting to develop an oral vaccine.
Vaccination 94
94 
Pfizer/BioNTech Begin Studies for Third Booster Dose and Development of COVID-19 Vaccine Variants
XTalks
MARCH 1, 2021
(NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. Related: Could Pfizer and BioNTech’s COVID-19 Vaccine be Stored at Standard Freezer Temperatures?
Vaccination 111
111 
Eyam Vaccines and Immunotherapeutics Reaches Agreement to License Next-Generation COVID-19 Vaccine Candidates from the University of British Columbia
The Pharma Data
DECEMBER 2, 2020
This License Agreement represents an important corporate milestone. The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. EYAM anticipates rapid commencement of animal trials for these COVID-19 vaccine candidates.
Licensing 52
52 
Merck and Moderna to jointly develop personalised cancer vaccineÂ
Drug Discovery World
NOVEMBER 8, 2022
Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. .
Vaccination 52
52 
Pfizer and BioNTech seek FDA EUA for Omicron-based Covid-19 vaccine
Pharmaceutical Technology
AUGUST 23, 2022
5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.
Vaccination 130
130 
CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal
BioSpace
NOVEMBER 1, 2022
San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.
Vaccination 74
74 
FDA expected to make decision on Pfizer RSV vaccine in May
BioPharma Reporter
DECEMBER 8, 2022
The US Food and Drug Administration (FDA) has accepted Pfizerâs RSV vaccine Biologics License Application (BLA) for priority review: with a decision expected in May.
Vaccination 98
98 
Cyfendus Anthrax Vaccine Wins FDA Approval
XTalks
JULY 25, 2023
Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). What Is Anthrax? How Does Cyfendus Work?
FDA Approval 98
98 
FDA Considers Self Administered Nasal Flu Vaccine + Wayne Gretzky Features in GSK RSV Vaccine Ad – Xtalks Life Science Podcast Ep. 135
XTalks
NOVEMBER 8, 2023
In this episode, Ayesha talked about the FDA’s acceptance of AstraZeneca’s supplemental biologics license application (sBLA) for a self-administered option of its nasal influenza vaccine FluMist Quadrivalent. Hear more about the ad featuring the Canadian hockey icon.
Life Science 52
52 
U.S. FDA grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 vaccine
The Pharma Data
JULY 18, 2021
Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.
Licensing 52
52 
WHO recommends cost-effective and easily deployable malaria vaccine
Drug Discovery World
OCTOBER 3, 2023
The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). The developers expect additional regulatory approvals will follow shortly and R21/Matrix-M vaccine doses could be ready to begin wider roll-out next year.
Vaccination 59
59 
VaxAlta Inc. Announces License Agreement With Scandinavian Biopharma
BioTech 365
DECEMBER 21, 2021
Announces License Agreement With Scandinavian Biopharma VaxAlta Inc. Announces License Agreement With Scandinavian Biopharma Scandinavian Biopharma has obtained a global license for VaxAlta Inc.’s s intellectual property for the development of a new Campylobacter jejuni vaccine for humans. VaxAlta Inc.
Licensing 52
52 
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Drug Discovery Today
JULY 7, 2022
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)
Licensing 40
40 
Preclinical data supports arenaviral therapeutic vaccine for hepatitis B
Drug Discovery World
OCTOBER 27, 2023
HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.
Vaccination 52
52 
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
BioTech 365
AUGUST 2, 2021
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development — Accelerates development of current Sanofi licensed programs in vaccines … Continue reading →
Vaccination 40
40 
Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy
XTalks
APRIL 26, 2021
After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.
Vaccination 105
105 
Novavax Vaccine Becomes First FDA-Authorized Protein Vaccine for COVID-19
XTalks
JULY 19, 2022
The US Food and Drug Administration (FDA) has given emergency use authorization (EUA) to Novavax’s COVID-19 vaccine, making it the fourth authorized vaccine in the US against COVID-19. The vaccine is branded as Nuvaxovid outside the US with approvals/authorizations in Canada, the EU, UK, Australia and South Korea.
Vaccination 94
94 
Gilead and Gritstone Ink $785 Million+ Deal to Develop HIV Cure
BioSpace
JANUARY 31, 2021
Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
Licensing 111
111 
Pfizer Shares Positive Phase III Data for Maternal RSV Vaccine Candidate
XTalks
NOVEMBER 4, 2022
Pfizer announced positive top-line data from a Phase III trial evaluating its respiratory syncytial virus (RSV) prefusion vaccine candidate, RSVpreF (or PF-06928316) for pregnant individuals to help protect their infants from RSV disease after birth. Related: Pfizer to Acquire RSV Antiviral Developer ReViral in $525 Million Deal.
Vaccination 97
97 
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine
The Pharma Data
MAY 7, 2021
The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S. Since then, the companies have delivered more than 170 million doses of the vaccine across the U.S. We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S.
Licensing 52
52 
Pfizer/BioNTech strike back in Moderna COVID vaccine lawsuit
pharmaphorum
DECEMBER 6, 2022
Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent despite centring on their mRNA-based vaccines for COVID-19. It also waived its rights to bring the lawsuit when it pledged not to sure other COVID-19 vaccine producers during the pandemic, according to Reuters.
Vaccination 81
81 
Let's personalize your content